The detection of CMV pp65 and IE1 in glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 103, Issue 2, 2011, Pages 231-238

  Lucas, Kenneth G ^a,b   Bao, Lei ^a,b   Bruggeman, Richard ^a,b   Dunham, Kimberly ^a,b   Specht, Charles ^a,b  

^a PENN STATE CHILDREN S HOSPITAL   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Cytotoxic T lymphocytes; Glioblastoma multiforme; Immunotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PARAFFIN; PROTEIN IE1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN LOCALIZATION; UPREGULATION;

ADULT; AGED; BRAIN NEOPLASMS; CELL SEPARATION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS;

EID: 79959834313     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0383-6     Document Type: Article

References (48)

1. Davis FG et al (2001) Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 3(3):152-158 (Pubitemid 33674106)
2. Surawicz TS et al (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40(2):151-160 (Pubitemid 29010168)
3. Zhang JG et al (2007) Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13(2 Pt 1):566-575
4. Saikali S et al (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81(2):139-148 (Pubitemid 44963972)
5. Sampson JH et al (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 93(19):10399-10404
6. Yu JS et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61(3):842-847 (Pubitemid 32175145)
7. Mitchell DA, Fecci PE, Sampson JH (2008) Immunotherapy of malignant brain tumors. Immunol Rev 222:70-100 (Pubitemid 351430365)
8. Liau LM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11(15):5515-5525 (Pubitemid 41060828)
9. Merchant RE et al (1988) Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23(6):725-732 (Pubitemid 19018774)
10. Lillehei KO et al (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28(1):16-23
11. Dillman RO et al (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27(5):398-404 (Pubitemid 39121929)
12. Serraino D et al (2005) Infection with Epstein-Barr virus and cancer: an epidemiological review. J Biol Regul Homeost Agents 19(1-2):63-70
13. Eiben GL et al (2003) Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16(2):111-121 (Pubitemid 36734789)
14. Bosch FX et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9(2):191-211, v
15. Vilchez RA, Butel JS (2003) Simian virus 40 and its association with human lymphomas. Curr Oncol Rep 5(5):372-379 (Pubitemid 38898806)
16. Harkins L et al (2002) Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360(9345):1557-1563 (Pubitemid 35356371)
17. Cobbs CS et al (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62(12):3347-3350 (Pubitemid 34651375)
18. Samanta M et al (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170(3):998-1002 (Pubitemid 36999620)
19. Mitchell DA et al (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10(1):10-18 (Pubitemid 351250896)
20. Scheurer ME et al (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116(1):79-86
21. Poltermann S et al (2006) Lack of association of herpesviruses with brain tumors. J Neurovirol 12(2):90-99 (Pubitemid 44574600)
22. Lau SK et al (2005) Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 18(6):838-843 (Pubitemid 40780518)
23. Cinatl J et al (2008) Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for a viral infection in tumor progression. FEMS Microbiol Rev 28:59-77 (Pubitemid 38224507)
24. Hagemeier C et al (1994) Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J 13(12):2897-2903 (Pubitemid 24191700)
25. Fortunato EA et al (1997) Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other. J Virol 71(11):8176-8185 (Pubitemid 27446393)
26. Tsai HL et al (1996) Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J Biol Chem 271(7):3534-3540
27. Bao L et al (2008) Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14(10):1156-1162
28. Sun Q et al (2000) B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol 165(7):4105-4111 (Pubitemid 32057322)
29. Yang I et al (2004) Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 100(2):310-319 (Pubitemid 38140236)
30. Read SB et al (2003) Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. J Interferon Cytokine Res 23(7):379-393 (Pubitemid 36876284)
31. Serrano A et al (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-20-deoxycytidine treatment. Int J Cancer 94(2):243-251 (Pubitemid 32911420)
32. Ogura T et al (1986) Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol 67(Pt 12):2605-2616 (Pubitemid 17197591)
33. Luo MH, Fortunato EA (2007) Long-term infection and shedding of human cytomegalovirus in T98G glioblastoma cells. J Virol 81(19):10424-10436
34. Sabatier J et al (2005) Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer 92(4):747-750 (Pubitemid 40460613)
35. Staras SA et al (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43(9):1143-1151 (Pubitemid 44632796)
36. Boeke CE et al (2008) CMV antibody prevalence and seroincidence in plateletpheresis donors. J Clin Apher 23(2):63-65 (Pubitemid 351656256)
37. Thurner B et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11):1669-1678 (Pubitemid 30002348)
38. Coulie PG et al (2002) Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 188:33-42 (Pubitemid 35398863)
39. Ho WY et al (2006) In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310(1-2):40-52
40. Borysiewicz LK et al (1988) Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168(3):919-931
41. Liu YN, Kari B, Gehrz RC (1988) Human immune responses to major human cytomegalovirus glycoprotein complexes. J Virol 62(3):1066-1070 (Pubitemid 18068667)
42. Ploegh HL (1998) Viral strategies of immune evasion. Science 280(5361):248-253
43. Oshiro S et al (2000) Response of MHC class-1 antigen on rat glioma cells to cytokines. Anticancer Res 20(1C):605-610 (Pubitemid 30189699)
44. Piguet V et al (1986) Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones. J Natl Cancer Inst 76(2):223-228 (Pubitemid 16130002)
45. Wen PY, Lampson MA, Lampson LA (1992) Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol 36(1):57-68
46. Mitchell D et al (2008) Efficacy of a phase II vaccine targeting cytomegalovirus antigens in newly-diagnosed GBM. J Clin Oncol 26:2042
47. Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359(5):539-541
48. Bao L, Sun Q, Lucas KG (2007) Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother (1997) 30(5):557-561